Register

Medical Oncology

CAR-T   

Questions discussed in this category

What is your treatment of choice for triple class refractory multiple myeloma?
CAR-T (any specific preference of product?) vs bispecific antibodies vs any other specific agents not previously utilized?
2 Answers available
How do you incorporate radiation therapy in patients undergoing CAR T-cell therapy for DLBCL?
2 Answers available
How do you determine when to give a second CAR-T cell infusion to a pediatric or young adult patient with relapsed/refractory ALL?
2 Answers available
Do you offer fertility preservation to patients prior to CAR-T therapy?
Do you limit it to post-pubertal patients? Do you offer it only if they will proceed with bone marrow transplantation after CAR-T?
1 Answer available
How do you incorporate CAR-T cell therapy in the second-line setting for DLBCL in transplant-eligible patients?
How do you assess chemosensitive vs chemorefractory disease? Given the results of ZUMA-7, TRANSFORM, and BELINDA - will you be altering your current ...
4 Answers available


Papers discussed in this category

Blood, 2020 Sep 23
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies.
International journal of radiation oncology, biology, physics, 2019-12-01
Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.
The Lancet. Oncology, 2019-01
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Molecular therapy : the journal of the American Society of Gene Therapy, 2018-11-07
Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape.
Cancer immunology research, 2019-07
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy.
Br J Haematol, 2020 Mar 5
Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.
Lancet, 2020 Sep 01
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Blood Adv,
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.
Int J Radiat Oncol Biol Phys, 2020 May 22
Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma.
The New England journal of medicine, 2017-12-28
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Radiother Oncol, 2021 Dec 7
Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?
Int J Radiat Oncol Biol Phys, 2021 Dec 1
Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy.

Related Topics in Medical Oncology

Copyright © 2025 theMednet
All Rights Reserved.